Streamlining the TIL Therapy Pipeline for Melanoma

Ravi Amaravadi, MD, of Penn Medicine’s Abramson Cancer Center, explains the operational strategies utilized at his institution to drastically compress the timeline for initiating tumor-infiltrating lymphocyte (TIL) therapy. Given the aggressive nature of advanced melanoma, minimizing the time between a patient's initial consultation and cellular harvest is critical. To achieve this, the institution focuses on consolidating clinical visits and expediting all requisite insurance and diagnostic testing.

The acceleration process begins the moment a patient’s name is received. The medical team immediately coordinates with the cell therapy department to pre-order all diagnostic tests required by insurance providers for the formal evaluation. Simultaneously, a dedicated nurse navigator coordinates a single-day, multidisciplinary appointment. During this visit, the patient is evaluated concurrently by a medical oncologist and the surgical oncologist who will perform the cellular harvest.

This coordinated approach allows the clinical team to efficiently determine if the patient meets the fitness criteria for TIL therapy, identify a resectable tumor mass for harvest, and outline any outstanding diagnostic requirements. Crucially, it enables the team to immediately reserve a manufacturing slot that aligns precisely with scheduled operating room time. By leveraging this highly synchronized strategy, the institution has successfully moved eligible patients from their very first consultation to the actual TIL harvest within a single week.

Although this accelerated pipeline is highly effective, Amaravadi notes that individual patient variables can introduce clinical uncertainties. For instance, determining whether to order an additional PET scan prior to surgery can introduce delays. Because every case presents unique clinical nuances, flexibility is required. However, establishing a rapid, standardized framework remains essential to ensuring that patients with advanced melanoma can safely access this complex cellular therapy before their disease progresses further.